Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment

Head and Neck

Volumn 29, Issue 4, 2007, Pages 401-411

  Couch, Marion ^a,c   Lai, Victor ^a   Cannon, Trinitia ^a   Guttridge, Denis ^b   Zanation, Adam ^a   George, Jonathan ^a   Hayes, D Neil ^a   Zeisel, Steven ^c   Shores, Carol ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c IL   (United States)

Author keywords

Cancer cachexia and anorexia; Muscle wasting; Weight loss

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CELECOXIB; CORTICOSTEROID; CYPROHEPTADINE; DEXAMETHASONE; DRONABINOL; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; METOCLOPRAMIDE; NANDROLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; RETINOL;

ABDOMINAL CRAMP; ADRENAL SUPPRESSION; BLOATING; BONE METASTASIS; CACHEXIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; DELIRIUM; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG EFFECT; DRUG MEGADOSE; DYSPHORIA; FATIGUE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; IMMUNE DEFICIENCY; INCIDENCE; LIBIDO DISORDER; MEDICAL LITERATURE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEARCH ENGINE; SIDE EFFECT; TASTE AVERSION; TASTE DISORDER; THROMBOPHLEBITIS; THRUSH; VOMITING; WEIGHT GAIN;

CACHEXIA; HEAD AND NECK NEOPLASMS; HUMANS; NUTRITIONAL SUPPORT; QUALITY OF LIFE; SURVIVAL RATE;

EID: 34247250705     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20447     Document Type: Review

References (58)

1. Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology center. Eur J Cancer Care 1999;8:133-136.
2. Buntzel J, Kuttner K. Value of megestrol acetate in treatment of cachexia in head-neck tumors. Laryngorhinootologie 1995;74:504-507.
3. Tisdale MJ. Cachexia in cancer patients. Nature 2002;2: 862-871.
4. Bruera E. ABC of palliative care. Anorexia, cachexia and nutrition. BMJ 1997;315:1219-1222.
5. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002;52: 72-91.
6. Mantovani G, Mededdu C, Maccio A, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidermiol Biomarkers Prev 2004;13:1651-1659.
7. Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol 2003;67:213-220.
8. Kim HL, Han K, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 2004;171:1810-1813.
9. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-509.
10. Dewys WD. Weight loss and nutritional abnormalities in cancer patient: incidence, severity, and significance. In: Calmar KC, Fearon KCH, editors. Nutritional support for the cancer patient. London: WB Saunders. p 251-261.
11. Inagaki J, Rodriquez V, Bodey GP. Causes of death in cancer patients. Cancer 1974;33:568-571.
12. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-497.
13. Guttridge DC, Mayo MW, Madrid LV, Wang C, Baldwin AS. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
14. Kwak KS, Zhou X, Solomon V, et al. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alplha-II during cancer cachexia. Cancer Res 2004;64:8193-8198.
15. Wyke SM, Tisdale MJ. NF-kappa B mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 2005;92:711-721.
16. Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
17. Chance WT, Balasubramaniam A, Thompson H. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996;17:797-801.
18. Gayle D, Ilyin SE, Plata-Salaman CR. Central nervous system IL-1beta system and neuropeptide Y mRNA during IL-1beta-induced anorexia in rats. Brain Res Bull 1997;44:311-317.
19. Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114:370-378.
20. Zhou W, Jiang Z, Tian J, Jiang J, Li N, Li J. Role of NF-κB and cytokine in experimental cancer cachexia. World J Gastroenterol 2003;9:1567-1570.
21. Mendell JR, Engel WK. The fine structure of type II muscle fiber atrophy. Neurology 1971;21:358-365.
22. Tomlinson BE, Walton JN, Rebeiz JJ. The effects of ageing and of cachexia upon skeletal muscle. A histopathological study. J Neurol Sci 1969;9:321-346.
23. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-255.
24. Sarhill N, Mahmoud FA, Christie R, Tahir A. Assessment of nutritional status and fluid deficits in advanced cancer. Am J Hosp Palliat Care 2003;20:465-473.
25. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy - a pilot study. Support Care Cancer 2005;13: 270-274.
26. Fang F, Liu Y, Tang Y, Wang C, Ko S. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 2004; 100:425-432.
27. Petruson KM, Silander EM, Hammerlid EB. Quality of life as predictor or weight loss in patients with head and neck cancer. Head Neck 2005;27:302-310.
28. Kim HL, Han K, Zisman A, Figlin RA, Bellidegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 2004;171:1810-1813.
29. Nguyen TV, Yueh B. Weight loss predicts mortality after recurrent oral cavity and oropharyngeal carcinomas. Cancer 2002;95:553-562.
30. Logemann JA, Pauloski BR, Rademaker AW, et al. Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation. Head Neck 2003;25:432-437.
31. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-634.
32. 2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer. 2005;92:876-881.
33. Von Roenn JH, Paice JA. Control of common, non-pain cancer symptoms. Semin Oncol 2005;32:200-210.
34. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophyinduced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
35. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome. A systematic review of randomized clinical trials. Ann Oncol 2001;12:289-300.
36. Mantovani G, Maccio A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995;25:135-141.
37. Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R. Supportive treatment with megestrol acetate during radio (chemo)therapy in patients with tumors in the head-neck area. A randomized study. Strahlenther Onkol 1996;172: 162-168.
38. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10:14-18.
39. Desport JS, Gory-Delabaere G, Blanc-Vincent MP, et al. Practice guideline. Standards, options and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer 2003;89(suppl 1):S98-S100.
40. Russell ST, Tisdale MJ. Effect of eicoasapentaeonic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot Essent Fatty Acids 2005;72:409-414.
41. Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90:996-1002.
42. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-86.
43. Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Downregulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Colch) 1997;92:215.
44. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut 2003;52:1479.
45. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind placebo-controlled study. J Clin Oncol 2003;21:129.
46. Hopkins K. Food for life, love and hope: an exemplar of the philosophy of palliative care in action. Proc Nutr Soc 2004;63:427-429.
47. Davis TW, Zweifel BS, O'Neal JM, et al. Inhibition of cyclooxygenase-2 by Celecoxib reverses tumor-induced wasting. J Pharm Exp Ther 2004;308:929-934.
48. Lundholm K, Daneryd P, Korner U, Hyltander A, Bosaeus I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004; 24:505-512.
49. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004;111:592-595.
50. McCarthy DO, Whitney P, Hitt A, Al-Majid S. Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 2004;27:174-184.
51. Enomoto A, Rho MC, Fukami A, Hiraku O, Komiyama K, Hayashi M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun 2004; 323:1096-1102.
52. Jatoi A, Egner J, Loprinzi CL, et al. Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer 2004;12:640-644.
53. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbre1), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10:6528-6534.
54. Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005;16:73-78.
55. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17:677-686.
56. Schroeder ET, Zheng L, Yarasheski KE. Treatment with oxandrolone and the durability of effects in older men. J Appl Physiol 2004;96:1055-1062.
57. Takala J, Ruokonen E, Webster NR. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-792.
58. Rubinfeld J, Handani M, Taylor JE, et al. Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells. Eur J Endocrinol 2004;151:787-795.